Please login to the form below

Not currently logged in
Email:
Password:

Chugai appoints US CMO

Athos Gianella-Borradori has clinical experience at Novartis and Merck Serono

Japanese company Chugai Pharma has named Dr Athos Gianella-Borradori as chief medical officer of its US subsidiary.

Dr Gianella-Borradori was most recently chief medical officer at Norwegian firm Clavis Pharma having joined the company in 2010 from Merck Serono.

At Merck Serono he served as head of clinical development for small molecules in onco-haematology and his prior experience includes clinical roles across Europe at Novartis, Crucell, Bavarian Nordic and Cyclacel.

The appointment at Chugai Pharma marks Dr Gianella-Borradori's first US role. As chief medical officer he has responsibility for all clinical activity in the US and will participate in a leadership role on scientific and translational committees for its Tokyo-headquartered parent company.

He will also represent Chugai, in which Swiss pharma company Roche owns a majority stake, in its relationships with the US FDA, academia, clinical investigators and patient communities.

30th April 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....